Details for New Drug Application (NDA): 201739
✉ Email this page to a colleague
The generic ingredient in AUVI-Q is epinephrine. There are twenty-one drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the epinephrine profile page.
Summary for 201739
| Tradename: | AUVI-Q |
| Applicant: | Kaleo Inc |
| Ingredient: | epinephrine |
| Patents: | 10 |
Pharmacology for NDA: 201739
| Mechanism of Action | Adrenergic alpha-Agonists Adrenergic beta-Agonists |
Medical Subject Heading (MeSH) Categories for 201739
Suppliers and Packaging for NDA: 201739
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739 | NDA | HF Acquisition Co LLC, DBA HealthFirst | 51662-1320 | 51662-1320-1 | .3 mL in 1 DOSE PACK (51662-1320-1) |
| AUVI-Q | epinephrine | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | 201739 | NDA | HF Acquisition Co LLC, DBA HealthFirst | 51662-1320 | 51662-1320-2 | 2 DOSE PACK in 1 CARTON (51662-1320-2) / .3 mL in 1 DOSE PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS | Strength | EQ 0.3MG/DELIVERY | ||||
| Approval Date: | Aug 10, 2012 | TE: | BX | RLD: | Yes | ||||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Apr 30, 2025 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Dec 12, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | ⤷ Get Started Free | Patent Expiration: | Mar 12, 2028 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Expired US Patents for NDA 201739
Complete Access Available with Subscription
